Contact Us
Contact Us
Press Releases

New Coalition Dedicated To Fostering American Synthetic Biology Manufacturing Launched Today

The SynBio Coalition, Backed by Three Industry Leaders, Says Innovation is Key for American Global Leadership, Job Creation, Greater Security, and the New Green Economy; Pledges to Work with Government, Industry

WASHINGTON, April 14, 2021 /PRNewswire/ — Today, three leading synthetic biology companies announced the launch of the Synthetic Biology (SynBio) Coalition (www.synbioco.com) to promote investment and support for the American synthetic biology industry. Synthetic biology is a field of science that involves redesigning microorganisms for useful purposes.  It is already being leveraged across many industries, including pharmaceuticals and medical treatments, food and agriculture, plastics, apparel, energy, consumer electronics, and personal and home care items, and is poised to have a significant impact on American economic growth over the coming years.

Working in collaboration with the US federal government, the SynBio Coalition aims to support the development and growth of the world’s advanced biomanufacturing industry in the United States, contributing to technologies that will improve access to medicine, create more sustainable and productive farming practices, help transform industrial manufacturing, and unlock a next generation of products across numerous industries.   

The SynBio Coalition is backed by three of America’s leading synthetic biology companies: Antheia, based in Menlo Park, California; Genomatica, based in San Diego, California; and Ginkgo Bioworks, based in Boston, Massachusetts.

“Over the last decade, synthetic biology’s advances have moved out of the lab and into the real economy, making the potential of this disruptive technology increasingly apparent,” said Christina Smolke, CEO and co-founder at Antheia. “As the technology continues to scale, it’s essential that industry and government work together to ensure that synbio’s advances translate into meaningful innovations that improve people’s lives.”

“America’s strengths in synbio innovation and growing crops can power a new era of industrial growth and prosperity, while making the products we use every day, better and more sustainable,” said Christophe Schilling, co-founder and CEO at Genomatica. “Synbio manufacturing of widely-used materials can bring back many industries that have moved overseas. This coalition is a great step in building broad support for the policies needed to drive this opportunity.” 

“We see the potential for biology to transform all the industries that produce physical goods,” said Jason Kelly, co-founder and CEO of Gingko Bioworks. “The ongoing efforts of the US government to invest in next generation technologies, including synthetic biology, are laying the groundwork for continued investment, governance, and prioritization of this transformative technology at a national scale.”

Creating a national synthetic biology infrastructure and manufacturing base will strengthen the United States’ position as a global leader in technology and innovation, help grow a robust and resilient domestic supply chain, support the development of a next-generation workforce, and empower next generation, sustainable manufacturing.

Global leadership:  America is the current global leader in the development of synthetic biology. The coalition believes that continued investment in synthetic biology, research infrastructure and manufacturing capacity is critical to realizing the full potential of this industry and maintaining American global leadership.   

American jobs: Synthetic biology holds tremendous promise for American workers. The coalition believes that continued investment in this emerging field of science will lead to the creation of more high-paying STEM and manufacturing jobs in both rural and urban areas across the United States.

Supply chain security:  The COVID-19 pandemic has exposed significant supply chain challenges for US companies in critical industries.  The coalition believes that a greater investment in an American synthetic biology manufacturing base will increase US resilience and national security by decreasing our reliance on overseas products, including Active Pharmaceutical Ingredients (APIs), Key Starting Materials (KSMs), and widely used chemicals and materials. 

Green economy:  Building a greener economy is of critical importance to business leaders, public officials, and consumers.  The coalition believes that synthetic biology builds cleaner solutions for a host of industries dedicated to lowering their emissions and having an improved environmental footprint.

The three steering committee members of SynBio Coalition are:

  • Antheia is unlocking the medicinal power of nature. Its synthetic biology platform surpasses the limits of conventional drug discovery and manufacturing through a novel approach to whole-cell engineering — reconstructing complex molecules in yeast to bring to market next-generation plant-inspired medicines. Antheia’s team of scientists and technologists is headquartered in Menlo Park, California. For more information, visit www.antheia.bio.
  • Genomatica is remaking everyday products and materials with more sustainable, high-performance ingredients, made from renewable sources like plants rather than fossil fuels. Genomatica’s first commercial products and partnerships with leading industrial firms and brands are already having high impact in plastics and cosmetics, with more coming in apparel, homecare, auto parts and more. Genomatica’s Innovation Center is in San Diego, California. For more information, visit www.genomatica.com.
  • Headquartered in Boston, Ginkgo Bioworks uses the most advanced technology on the planet—biology—to grow better products. The company’s cell programming platform is enabling the growth of biotechnology across diverse markets, from food to fragrance to pharmaceuticals. For more information, visit www.ginkobioworks.com.

ABOUT THE SYNBIO COALITION:  The SynBio Coalition aims to turn the US into the home of the world’s most secure and technologically advanced biomanufacturing industry.  Founded by three of the leading synthetic biology companies, the SynBio Coalition is a non-partisan group of academics, business leaders, and government representatives dedicated to advancing synthetic biology as a driver of technological innovation and economic growth. 

SOURCE Synthetic Biology Manufacturing Coalition

Richard Sherwin

Head of Commercialization

Richard is an industry veteran with more than 30 years of experience in the KSM, API, and intermediate markets. He is responsible for leading the commercialization and revenue generation for Antheia’s robust pipeline of products. Richard brings an exceptional track record of leading international sales teams, driving revenue growth, building strategic partnerships, and delivering innovative products to market, including ANDA and NDA developments. Richard led commercial efforts at some of the leading global pharmaceutical companies and most recently, built his own consultancy business advising a range of clients, including $1B divisions of major multinationals.

Appropriate regulatory submissions will be prepared and submitted to support Antheia’s customers who need to reference and access necessary process-related information.

Yihui Zhu, PhD

Head of Fermentation

Yihui leads the fermentation team at Antheia. With over 25 years of hands-on experience in the field, he brings in-depth knowledge and expertise in microbial metabolism and fermentation process development. He is also skilled in developing comprehensive fermentation data collection, analysis, and visualization systems. Prior to joining Antheia, he served as a fermentation lead at Intrexon and Codexis where he successfully built fermentation labs and teams and led multiple biofuel and biochemical projects to reach stretch milestones and tech transfer. Yihui is passionate about the potential of fermentation and is dedicated to advancing the field through innovative research and development.

Yen-Hsiang Wang, PhD

Head of Strategy, Partnerships, and Finance

Yen-Hsiang leads strategy, partnerships and finance at Antheia. He completed his M.S. and Ph.D. in Bioengineering at Stanford, with extensive research experience in synthetic biology, metabolic engineering and computational modeling. Before joining Antheia, he worked at McKinsey and Tencent with a strong focus in corporate strategy and big data/advanced analytics. At Tencent, he served as Director of Strategy and Business Development for the AI Lab, leading corporate initiatives in healthcare AI/ML applications and commercialization. He also served in AI4H (Artificial Intelligence for Health), a collaboration between WHO and ITU, to establish global standards for AI in healthcare.

Audrey Wang

Head of Financial Planning and Analysis

Audrey leads financial planning and analysis at Antheia. With an MBA from Washington University in St. Louis, Audrey is passionate about leveraging financial analysis, digital technology, and data analytics to guide companies in making optimal investments and strategic business decisions. Audrey has a decade of experience in helping companies solve unique problems and creating long-term impact with unconventional approaches. Before joining Antheia, she was at Vir Biotechnology and Merck where she led various FP&A workstreams, including investment valuation, asset prioritization, and manufacturing sites operation finance support. Audrey completed CFA Level II and passed the U.S. CPA exam in 2011.

Antonij Tjahjadi, CPA

Head of Accounting

Antonij Tjahjadi leads accounting at Antheia and holds active CPA license. He joined Antheia with more than 20 years of experience in corporate accounting, bringing deep expertise in ramping up accounting operations for start-up companies, SEC reporting/technical accounting, and SOX implementation efforts. Before joining Antheia, he held various leading roles in both public and private company settings, including directing accounting functions at Ambys Medicines, where he successfully implemented Netsuite with Point Purchasing integration and set up various accounting policies and processes, and played a key role in the initial public offering of Nutanix, Inc.

Ken Takeoka

Head of Biology

Ken leads the Biology team at Antheia, which incorporates both strain and protein engineering functions. He has more than 16 years of experience in the synthetic biology field, working with leading companies, including Amyris and Novartis. One of his passions is molecular biology tool development and he previously worked to build the foundation for the automated strain engineering pipeline at Amyris. At Novartis, he modernized the molecular biology techniques and established a platform to model mechanisms of antibiotic resistance in a range of organisms.

Suzanne Sato

Head of Downstream Processing

Suzy leads downstream chemistry processes at Antheia. She has 19 years of experience in process development, including route development through synthetic chemistry and scale-up of small molecule APIs for GPCR targets under cGMP for Phase I-III trials. Before joining Antheia, Suzy led a full DSP team at Amyris where she successfully pivoted developments from biofuels hydrocarbon products to pharmaceutical intermediate, flavor, fragrance and nutraceutical products. She led a team that scaled 11 products and took five products to commercial manufacturing.

Farrah Pulce, PMP

Head of Project Management

Farrah leads program and project management at Antheia. She has over 20 years of experience leading program and project management, operations, and engineering for companies across the CPG, aerospace, and automotive industries. Prior to joining Antheia, Farrah implemented and led the sustaining program management team at Impossible Foods. She also led product operations, project management, and cost optimization at Blue Bottle Coffee and Tyson Foods to develop and commercialize new products. As a certified project management professional (PMP), Farrah has a proven record of successful project delivery, improving project management practices, and building collaborative teams.

Jordyn Lee

Head of Communications

Jordyn leads communications and external affairs at Antheia. She brings a decade of multidisciplinary communications experience in helping companies make complex science and technology accessible to broad audiences, all while maintaining technical accuracy and integrity. She has a passion for visionary storytelling and translating impact across the entire communications ecosystem – her work has spanned from public relations to corporate communications to marketing. Jordyn has served as an advisor to a number of different life sciences companies and most recently led corporate communications at Amyris.

Ben Kotopka, PhD

Head of Data Science

As Head of Data Science at Antheia, Ben manages in-house software development and external partnerships for storing and interpreting research data, executing bioinformatics analyses, and streamlining business processes. Prior to Antheia, Ben worked as an academic researcher at the intersection of machine learning, bioinformatics, and synthetic biology. Following this, as an entrepreneur and consultant, he developed and deployed data science solutions for biotechnology applications ranging from metabolomics-driven compound discovery to MRI segmentation.

Guerin Kob

Head of Supply Chain

Guerin is responsible for leading the design, development, management and improvement of Antheia’s end-to-end global supply chain. He has over 15 years of experience leading high-performing supply chain and procurement teams at leading biotechnology and specialty chemical companies, with extensive experience in process development and end-to-end supply chain optimization. Prior to joining Antheia, Guerin served as Senior Director of Global Supply Chain for Sumitomo Chemical’s biotechnology division with Valent Biosciences, where he led the end-to end supply chain including procurement, logistics and distribution, integrated business planning, materials management, customer service, and supply planning functions globally.

Pavel Aronov, PhD

Head of Bioanalytics

Pavel leads the Bioanalytics team at Antheia. He has 20 years of experience in analytical and clinical chemistry, mass spectrometry, chromatography, and metabolomics. Pavel built and led the original Chemistry and Analytics team at Impossible Foods enabling strain development, fermentation, DSP, regulatory, QC, and scale-up of leghemoglobin biomanufacturing. During his academic career at UC Davis and Stanford University Pavel developed a vitamin D assay used by all major clinical diagnostics laboratories and pioneered metabolomics studies to investigate kidney disease and microbiome.

Jesse Ahrendt

Head of Quality Assurance and Regulatory Affairs

Jesse has more than 25 years of experience in regulatory affairs, quality systems, manufacturing quality, and regulated industries, ranging from early- to late-stage pharmaceuticals, biomanufacturing, consumer care, and medical devices. He has supported global product launches and the underlying quality supply chain components in industries that require strict adherence to internationally accepted quality standards. Before Antheia, he led quality efforts at Zymergen and Sandoz, and supported many global pharmaceutical companies during his time in Biotech Consulting at NSF International, all to bring quality to the forefront in manufacturing, standardize global processes, and support customer regulatory requirements.

Heidi Pucel

Chief People Officer

Heidi is a results-driven human resources executive and HR business partner who leverages decades of experience in empowering, motivating, and inspiring to drive transformation within high-performing and rapidly-growing workforces. A certified executive coach and passionate advocate for people-oriented solutions, Pucel serves as a partner to executive teams to design programs that support employee development, engagement, and recruitment and retention. Pucel most recently served as Chief People Officer for Countsy, where she worked as an interim HR executive for clients in the biotechnology and software industries, such as Ceribell and Tune Therapeutics.

Zack McGahey

Chief Operating Officer

Zack is a leading executive in operations management, specializing in bioprocess engineering and manufacturing management. He has over 20 years of experience leading manufacturing functions for companies across the pharmaceutical, synthetic biology, diagnostics, and automotive industries. Before joining Antheia, Zack was VP of manufacturing and capex project management at Zymergen. He also gained experience managing commercial scale facilities operations for Tesla, where he was responsible for managing 10 million square feet of factory, lab and warehouse space during the Model 3 ramp.

Kristy Hawkins, PhD

Co-Founder & CSO

Kristy has over 20 years of experience in the field of synthetic biology, focusing on yeast metabolic engineering for the production of small molecules. She did the founding work on the benzylisoquinoline alkaloid pathway during her graduate studies and gained valuable industry experience at Amyris and Lygos. Kristy is an expert in tool development, high-throughput screening, and host strain and heterologous pathway engineering.

Christina Smolke, PhD

Co-Founder & CEO

Christina is a pioneer in synthetic biology and metabolic engineering, where she has over 20 years of experience. As Professor of Bioengineering and Chemical Engineering at Stanford University, her laboratory led the breakthrough research to engineer baker’s yeast to produce some of the most complex and valuable medicines known. Under her leadership, Antheia’s synthetic biology platform enables new possibilities for drug discovery and efficient, sustainable, transparent, and on-demand drug manufacturing at scale. Her vision and accomplishments have garnered numerous awards, including the Chan-Zuckerberg Biohub Investigator, NIH Director’s Pioneer Award, Nature’s 10, Novozymes Award for Excellence in Biochemical Engineering, and TR35 Award.

Antheia hosts U.S. Secretary of State Antony J. Blinken to showcase the impact of biotechnology innovation

Appropriate regulatory submissions will be prepared and submitted to support Antheia’s customers who need to reference and access necessary process-related information.